Ginkgo Bioworks DNA Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ginkgo Bioworks's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ginkgo Bioworks's deferred revenue?
- Ginkgo Bioworks (DNA) reported deferred revenue of $14.91M in Q1 2026.
- How has Ginkgo Bioworks's deferred revenue changed year-over-year?
- Ginkgo Bioworks's deferred revenue decreased by 55.7% year-over-year, from $33.65M to $14.91M.
- What is the long-term trend for Ginkgo Bioworks's deferred revenue?
- Over 5 years (2020 to 2025), Ginkgo Bioworks's deferred revenue has grown at a -28.3% compound annual growth rate (CAGR), from $99.65M to $18.95M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.